Search Results - "GHEYAS, Ferdous"

Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science by Trujillo, Maria E., Ayalasomayajula, Surya, Blaustein, Robert O., Gheyas, Ferdous

“…Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is approved for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF)…”
Get full text

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia by Patel, Munjal, Bellanti, Francesco, Daryani, Naveen M., Noormohamed, Nadia, Hilbert, David W., Young, Katherine, Kulkarni, Pooja, Copalu, William, Gheyas, Ferdous, Rizk, Matthew L.

“…In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL)…”
Get full text

Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension by Ait‐Oudhia, Sihem, Jaworowicz, David, Hu, Ziheng, Bihorel, Sébastien, Hu, Shuai, Balasubrahmanyam, Budda, Mistry, Bipin, Oliveira Pena, Janethe, Wenning, Larissa, Gheyas, Ferdous

“…Sotatercept is a breakthrough, first‐in‐class biologic, that is FDA‐approved for the treatment of pulmonary arterial hypertension (PAH). A population…”
Get full text

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant by Chawla, Akshita, Largajolli, Anna, Hussain, Azher, Kleijn, Huub, Ait‐Oudhia, Sihem, Anton, Judith, Krishna Ananthula, Hari, Nussbaum, Jesse, La Rosa, Carmen, Gheyas, Ferdous

“…Gefapixant, a P2X3‐receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a…”
Get full text

A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data by Dudášová, Julie, Laube, Regina, Valiathan, Chandni, Wiener, Matthew C., Gheyas, Ferdous, Fišer, Pavel, Ivanauskaite, Justina, Liu, Frank, Sachs, Jeffrey R.

“…Vaccine efficacy is often assessed by counting disease cases in a clinical trial. A new quantitative framework proposed here (“PoDBAY,” Probability of Disease…”
Get full text

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression by MIRZA, Asra, QUN WU, GREENE, Jonathan R, SUXING LIU, LUQUAN WANG, MCCLANAHAN, Terri, BISHOP, W. Robert, GHEYAS, Ferdous, WEI DING, HUTCHINS, Beth, HOCKENBERRY, Tish, KIRSCHMEIER, Paul

“…The temporal gene expression profile during the entire process of apoptosis and cell cycle progression in response to p53 in human ovarian cancer cells was…”
Get full text

Human members of the eukaryotic protein kinase family by Kostich, Mitch, English, Jessie, Madison, Vincent, Gheyas, Ferdous, Wang, Luquan, Qiu, Ping, Greene, Jonathan, Laz, Thomas M

“…Eukaryotic protein kinases (EPKs) constitute one of the largest recognized protein families represented in the human genome. EPKs, which are similar to each…”
Get full text

Microarray profile of differentially expressed genes in a monkey model of allergic asthma by Zou, Jun, Young, Simon, Zhu, Feng, Gheyas, Ferdous, Skeans, Susan, Wan, Yuntao, Wang, Luquan, Ding, Wei, Billah, Motasim, McClanahan, Terri, Coffman, Robert L, Egan, Robert, Umland, Shelby

“…Inhalation of Ascaris suum antigen by allergic monkeys causes an immediate bronchoconstriction and delayed allergic reaction, including a pulmonary…”
Get full text

Analysis of the ERK1,2 transcriptome in mammary epithelial cells by Grill, Constance, Gheyas, Ferdous, Dayananth, Priya, Jin, Weihong, Ding, Wei, Qiu, Ping, Wang, Luquan, Doll, Ronald J, English, Jessie M

“…MAPK (mitogen-activated protein kinase) pathways constitute major regulators of cellular transcriptional programmes. We analysed the ERK1,2…”
Get full text

Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development by Taylor, M K, Ginsburg, J, Hickey, A, Gheyas, F

“…The flow properties of typical tablet and capsule formulation excipients, active compounds, and representative formulation blends were tested with current and…”
Get full text

Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective by Mohamed, Mohamed‐Eslam F., Girish, Sandhya, Humeniuk, Rita, Nuthalapati, Silpa, Desai, Amit, Datta‐Mannan, Amita, Gheyas, Ferdous, Kanodia, Jitendra, Cheeti, Sravanthi, Zhu, Tong

Get full text

Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis by Trujillo, Maria E., Arrington, Leticia, Patel, Yogesh, Passarell, Julie, Wenning, Larissa, Blaustein, Robert O., Armstrong, Paul W., Meyer, Michaela, Becker, Corina, Gheyas, Ferdous

“…Vericiguat, a novel stimulator of soluble guanylate cyclase (sGC), is indicated for the treatment of patients following a hospitalization for heart failure or…”
Get full text

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program by Galluppi, Gerald R., Ahamadi, Malidi, Bhattacharya, Souvik, Budha, Nageshwar, Gheyas, Ferdous, Li, Chi‐Chung, Chen, Yuan, Dosne, Anne‐Gaëlle, Kristensen, Niels Rode, Magee, Mindy, Samtani, Mahesh N., Sinha, Vikram, Taskar, Kunal, Upreti, Vijay V., Yang, Jianning, Cook, Jack

“…A recent industry perspective published in this journal describes the benefits received by drug companies from participation in the MIDD Pilot Program. Along…”
Get full text

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma by Jacobs, Conrad R., Rapoport, Bernardo Leon, Cohen, Graham Lawrence, Lala, Mallika, Silva, Carolina De Miranda, Vaddady, Pavan, Gheyas, Ferdous, de Alwis, Dinesh, Sinha, Vikram, Akala, Omobolaji Oyekunle, Chartash, Elliot, Jain, Lokesh

“…Abstract Background: Pembrolizumab is approved for use across multiple cancers at a dose of 200 mg or 2 mg/kg Q3W or 400 mg Q6W administered as an IV infusion…”
Get full text

Identification of differentially expressed genes in a monkey model of allergic asthma by microarray technology by Zou, Jun, Young, Simon, Zhu, Feng, Xia, Lu, Skeans, Susan, Wan, Yuntao, Wang, Luquan, McClanahan, Terri, Gheyas, Ferdous, Wei, Din, Garlisi, Charles, Jakway, James, Umland, Shelby

Get more information

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation by Ahamadi, Malidi, Mehrotra, Nitin, Hanan, Nathan, Lai Yee, Ka, Gheyas, Ferdous, Anton, Judith, Bani, Massimo, Boroojerdi, Babak, Smit, Hans, Weidemann, Jonas, Macha, Sreeraj, Thuillier, Vincent, Chen, Chao, Yang, Minhua, Williams‐Gray, Caroline H., Stebbins, Glenn T., Pagano, Gennaro, Hang, Yaming, Marek, Kenneth, Venuto, Charles S., Javidnia, Monica, Dexter, David, Pedata, Anne, Stafford, Bob, Akalu, Mussie, Stephenson, Diane, Romero, Klaus, Sinha, Vikram

“…Leucine‐rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson’s disease (PD)…”
Get full text

Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects by Krishna, Rajesh, Gheyas, Ferdous, Corr, Christy, Cote, Josee, Liu, Yang, Wagner, John, Gutstein, David E.

“…Anacetrapib is a cholesteryl ester transfer protein inhibitor intended for the treatment of dyslipidemia. A phase 1 study was conducted to examine the…”
Get full text

Operating characteristics of stepwise covariate selection in pharmacometric modeling by Ahamadi, Malidi, Largajolli, Anna, Diderichsen, Paul M., de Greef, Rik, Kerbusch, Thomas, Witjes, Han, Chawla, Akshita, Davis, Casey B., Gheyas, Ferdous

“…Stepwise covariate modeling (SCM) is a widely used tool in pharmacometric analyses to identify covariates that explain between-subject variability (BSV) in…”
Get full text

Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects by Krishna, Rajesh, Gheyas, Ferdous, Liu, Yang, Cote, Josee, Laterza, Omar, Ruckle, Jon L., Wagner, John A., Denker, Andrew E.

“…Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of mixed dyslipidemia. The aim of the study was to…”
Get full text

Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects by Chen, Hanjing, Chen, Weili, Li, Hui, Xu, Hongrong, Yuan, Fei, Sheng, Lei, Liu, Chao, Lin, Pingping, Yang, Mengjie, Li, Xuening, Liu, Yang, Walker, Brittany Marie, Gheyas, Ferdous, Iwamoto, Marian, Stoch, S. Aubrey, Krishna, Rajesh

“…Introduction Anacetrapib is a novel, powerful cholesteryl ester transfer protein (CETP) inhibitor with bidirectional lipid regulation, which was developed for…”
Get full text